Bio-Rad Laboratories (BIO) net assets (shareholders' equity)

Net assets · fiscal 2025
$7.45B

Bio-Rad Laboratories (BIO) had net assets of $7.45B at the end of fiscal 2025 (December 31, 2025). That is 13.5% higher than the $6.57B of fiscal 2024. Figures as of 18 Nov 2026, 23:47 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$7.45B
Change on fiscal 2024
+13.5%
Growth, 5 years
−5.5% a year
Growth, 10 years
+11.6% a year
Highest on record
$13.69Bfiscal 2021
Lowest on record
$1.07Bfiscal 2008
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Bio-Rad Laboratories net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets shrank at a compound 5.5% a year; over ten years the rate was 11.6% a year. Across the 18 fiscal years on record (2008–2025), the highest was $13.69B in fiscal 2021 and the lowest $1.07B in fiscal 2008.

History · 18 fiscal years

Net assets by fiscal year

Bio-Rad Laboratories net assets (shareholders' equity), year by year

Bio-Rad Laboratories (BIO) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$7.45B 13.5% up
2024$6.57B 24.8% down
2023$8.74B 9.1% down
2022$9.62B 29.7% down
2021$13.69B 38.4% up
2020$9.89B 71.8% up
2019$5.76B 43.2% up
2018$4.02B 37.2% up
2017$2.93B 13.6% up
2016$2.58B 3.8% up
2015$2.49B 13.8% up
2014$2.18B 0.1% down
2013$2.19B 8.5% up
2012$2.02B 15.5% up
2011$1.74B 13.5% up
2010$1.54B 22.0% up
2009$1.26B 17.7% up
2008$1.07B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Bio-Rad Laboratories and comparable companies
CompanyNet assetsFiscal year
Ensign Group ENSG$2.23B2025
Vaxcyte PCVX$2.69B2025
Bio-Rad Laboratories BIO$7.45B2025
Molina Healthcare MOH$4.07B2025
Spyre Therapeutics SYRE$715.24M2025
Qiagen QGEN$3.78B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BIO

Bio-Rad Laboratories, figure by figure

Bio-Rad Laboratories (BIO) overview: price, valuation and scorecardAll health care companies by market value

Bio-Rad Laboratories net assets (shareholders' equity): questions and answers

What are Bio-Rad Laboratories's net assets?

Bio-Rad Laboratories (BIO) had net assets of $7.45B at the end of fiscal 2025 (December 31, 2025). That is 13.5% higher than the $6.57B of fiscal 2024.

What is the growth rate of Bio-Rad Laboratories's net assets?

Over the five fiscal years to 2025 net assets shrank at a compound 5.5% a year; over ten years the rate was 11.6% a year.

What are the highest and lowest net assets figures on record for Bio-Rad Laboratories?

Across the 18 fiscal years on record (2008–2025), the highest was $13.69B in fiscal 2021 and the lowest $1.07B in fiscal 2008.

How is Bio-Rad Laboratories's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Bio-Rad Laboratories it is on record here for 18 fiscal years, 2008 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Bio-Rad Laboratories (BIO) net assets (shareholders' equity)”, data as of 18 November 2026. https://funkfolio.com/stock/BIO/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.